#868: Tim’s Founder Kitchen — From Brainstorm to The President’s Office in Two Months (Featuring Jake Becraft, Strand Therapeutics)

Why does it matter? Because the answer genetic medicine gave for 30 years was always a lie — and one company just proved it by erasing cancer from a patient's organs.

Jake Becraft built Strand Therapeutics around a single provocation: that everyone in genetic medicine has been giving a cheap, hand-wavy answer to why the field is stuck. A stage-four melanoma patient — cancer in the lungs, organs, muscle, and bone, no options remaining — entered Strand's trial and came out 18 months later with no detectable lesions anywhere. That result changes what's possible. Here's what this episode reveals:

• The "delivery problem" cited for 30 years is actually three separate unsolved challenges — potency, specificity, and delivery — bundled into a convenient single excuse that kept the entire field trapped in the liver since the 1990s. • Strand documented abscopal responses reaching visceral, deep-organ metastases in multiple patients from the very first cohort, making it the first company known to do this at scale. • The US now requires $25 million and 18 months just to begin a Phase 1 trial, while China has industrialized early-stage clinical infrastructure faster and cheaper — and capital is following. • A messaging reframe — leading with the solution, not the crisis — moved a specific FDA reform idea from a brainstorming session to the President's legislative priorities in under two months.

The '30-year delivery problem' in genetic medicine is three problems in a trench coat — and everyone calling it one has been giving a cheap answer

"It's a delivery problem" — that's the answer every expert has given for 30 years when asked why IV genetic medicine hasn't moved past the liver. Becraft calls it hand-wavy and incomplete. "It's three children in their father's trench coat pretending to be an adult," he says. Inside that coat: potency, specificity, and delivery, all unsolved, all collapsed into one convenient label.

The liver has dominated genetic medicine since the 1990s because it filters blood, so injected medicines accumulate there. The field collectively shrugged and never left. "In genetic medicine, the joke is: step one, prove it works in the liver. Step two, question mark. Step three, we'll treat all these diseases. And after 30 years, we've really nailed step one."

Thirty years of investment in "better delivery vehicles" kept arriving at the same organ because potency and specificity were never treated as separate engineering problems. The diagnosis was perpetually incomplete, so every solution kept missing. Nobody was decomposing the challenge into its actual components.

What Strand built requires treating all three as distinct problems — then solving them together inside a programmable RNA architecture. The solution wasn't a cleaner delivery vehicle. It was a different frame for the whole problem.

Strand injected one tumor and watched a patient's lungs clear — the first documented abscopal response reaching visceral metastases at this scale

Two of the first three patients ever enrolled in Strand's Phase 1 trial — entered in summer 2024 — are still on the trial 18 months later. One arrived with melanoma metastasized to lungs, organs, muscle, and bone. They had already exhausted Keytruda, Opdivo, and multiple additional lines of therapy. Strand injected genetic medicine into a surface tumor. Eighteen months later: no detectable lesions anywhere.

The abscopal effect — treating one tumor to re-educate the immune system to hunt others — had been observed before, but narrowly. A lesion on the chest, a nearby shoulder lesion shrinks. Not the lungs. Not the organs. "You don't die from having tumors all over your skin," Becraft explains. "You die when they metastasize into your lungs and your liver."

That's the gap Strand claims to have crossed. "We are the first company that I'm aware of to show this extent of abscopal response in visceral, deep organ metastases in a multitude of patients, and really right off the bat." Not a one-off: two of three initial patients, still responding 18 months in. Phase 1 trials are typically safety studies — durable efficacy signals this early are, in his word, "fairly shocking."

The mechanism: Strand's RNA medicine tricks cancer cells into broadcasting distress signals that re-educate the immune system to find and eliminate tumors that had previously been hiding throughout the body.

A $750,000 CAR-T therapy that cures myeloma is medically irrelevant to nearly everyone who needs it

The best cancer drugs in the world can be useless products. CAR-T therapies — where immune cells are extracted from a patient, reprogrammed in a lab to hunt blood cancers, then reinfused — produce dramatic results in myeloma patients who had nothing else. The drug works. It also costs $750,000 to manufacture a single course and takes three months to produce. "It's very hard to see a world in which that drug has a large impact on the patient population," Becraft says flatly.

A good drug and a good product are different things, and most breakthrough therapies die at the product stage. Efficacy without compatible delivery infrastructure is just an expensive result accessible to a handful of patients near elite hospitals. The product question — can a patient actually receive this within how hospitals already operate? — is inseparable from the science question.

The better version of CAR-T, in Becraft's framing, reprogram those same immune cells while they're still inside the patient: a two-hour outpatient infusion, then go home. Same mechanism. Completely different product profile.

"If you want to have the largest impact in medicine, you need to make medicines that plug into existing infrastructure." This isn't a concession to the status quo — it's the design challenge. Infusion clinics, standard nursing staff, outpatient procedures. Strand is building the biology and the product model simultaneously, not treating them as sequential problems.

The US is paying $25 million to let China win the race for clinical trial infrastructure — and the window to reverse it is closing

Getting permission to give a new drug to a human for the first time in the United States requires an Investigational New Drug Application to the FDA. Strand's first IND was 22,000 pages. Between professional writers, required preclinical studies, and manufacturing documentation, Becraft puts the total cost at $25 million and 18 months — before a single patient is enrolled.

China and Australia skip that step. Both systems notify regulators and proceed directly to hospital review boards, which assess safety. "China has built an industrialized version of clinical trial infrastructure for first-in-human trials that is so efficient and massively quick," Becraft says. What started as a workaround for American companies running early trials offshore has become a self-reinforcing flywheel: faster trials attract capital, capital builds more Chinese infrastructure, Chinese-developed drugs eventually enter the US market. The innovation premium begins flowing the other way.

Inside the US, the $25 million IND cost forces companies toward elite, already-overburdened sites. Hundreds of hospitals across the country run no first-in-human trials at all. Patients who've exhausted standard care often can't access experimental treatments unless they travel to Houston or New York.

The fix Becraft advocates is a notification system modeled on Australia's CTN: companies notify regulators, IRBs make the safety call, the FDA focuses its oversight downstream on actual drug approval. He gives it 50-50 odds within two years. "If we don't do it, it is actually existential."

Two months from brainstorm to the President's desk: one reframe changed how a regulatory reform idea landed

Two months. That's the gap between a brainstorming session about messaging and the same reform idea appearing in the President's published legislative priorities.

Becraft had been telling the clinical trials story to policymakers problem-first: America is falling behind, capital is fleeing to China, the system is broken. "If you come to them and say, everything's bad and it's burning and we're done, honestly, what is anyone going to do?" The version that moved was structurally inverted — solution front and center, urgency as context, the decision-maker's agency made explicit before the depth of the problem was delivered.

The op-ed ran in the Washington Post. Congressional staff reached out within days. Becraft testified on the Hill. A few weeks later, the President's budget recommendations included language about removing barriers to early-stage experimental medicine access through FDA reform.

"No one will learn until they care. Your first goal is to make someone care about what you're doing. Then they'll learn." Scientists are uniquely poorly trained for this: in a lab, your audience arrives already curious. Everywhere else, that curiosity has to be earned before any information can transfer at all. Show the light at the end of the tunnel first. Let the full mechanics of why everything is broken follow once someone has a reason to care.

Biotech investors literally bet against companies that try to sell their own drugs — 'short the launch' is a rational trade, which tells you everything about the industry

"Short the launch." It's a real strategy. When a biotech company gets a drug approved and decides to commercialize it themselves rather than hand it to a pharma acquirer, public market investors frequently short the stock — betting the company will miss projections and the price will fall. They're often right. The commercial muscle atrophied so thoroughly across the industry that the trade works.

This is what an industry optimized entirely for acquisition looks like. Big pharma stopped building internal R&D and started buying small companies instead. Biotech capital formation adjusted, and now everyone designs for what the buyers want. "If the entire tech industry was reliant on Meta, Google, Netflix, whoever buying your company, you would see a lot weirder and less ambitious dynamics at the entrepreneurial side because you'd just be trying to figure out what is Sundar going to do a year from now."

The result is structural timidity. Genuinely innovative risk — the kind required to build platform-level infrastructure rather than a single 10%-better drug — can't be underwritten when you're designing for a specific acquirer's strategic roadmap. So it doesn't get funded. And medicine advances in whatever increments pharma's corp dev team finds digestible.

"The biotechnology industry will be dragged kicking and screaming into the future, or it will be built up in a new way from new players." Becraft says this without drama. It's just the math.

Almost every 'platform' claim in biotech is fundraising fiction — a real platform is organ-specific and payload-swappable, not theoretically universal

"People have been claiming medicines are platforms for 20 years in the biotech industry, and they've almost always been wrong." Becraft says this not as competitive shade but as a structural warning. The word platform inflates valuations. The claim gets made. The company turns out to have one drug in expansive language.

A genuine therapeutic platform means proven delivery infrastructure for a specific organ or cell type, into which any protein payload can be loaded. That means specific, not universal. Moderna built a COVID vaccine in 62 days only because they spent the 12 years before that building base technology — particles, sequences, manufacturing processes. "62 days from the identification of the COVID antigen... but they spent 12 years before that developing this sort of technology." The 62 days was payload-swapping. The platform took a decade.

Strand's claim is bounded and evidenced: a tumor delivery platform, proven in Phase 1 data. A T-cell delivery platform in development. Eventually kidney, brain, other organs. Each one distinct. "Injecting things into tumors is different than getting things to deliver to tumors autonomously through the bloodstream, which is different than getting to T cells, which is different than getting to your kidney, which is different than getting to your brain."

The SpaceX progression is the right frame: Falcon 1 to Falcon Heavy to Starship. You cannot start with Starship. Every legitimate platform in history was built incrementally on proven prior infrastructure. The ones who claim otherwise are selling something.

Strand's insiders already know the technology works — the broader market hasn't priced it in yet, and that gap is the whole bet

Strand is no longer asking whether the science works. The question now is how quickly the broader world can be brought to the same certainty. Becraft has a name for this moment: post-conviction pre-consensus. "It is the ones who know, know. We're no longer saying, can we do this? We're like, oh my god, this is going to work. But it's pre-consensus because not everyone has caught on yet."

Amazon traded at modest multiples for years while Bezos compounded internal certainty about what AWS would become. Around 2017 the market recognized it and the stock went from roughly $120 to over $1,500 in what felt like a sudden realization. The value was always there. Consensus arrived late.

The prescription Becraft draws from this is Bezosian in its simplicity: say what you're building, publicly, every single day, like a mantra. Not to move the stock — to attract the partners, capital, and talent who need to understand the direction before they can commit to it, and to stay anchored when exit ramps appear. "We are not our market cap. Understanding and reminding yourself about what you're building every single day helps you understand whether or not you need to get off the highway."

For founders and investors alike: identify the post-conviction pre-consensus window explicitly. Then invest disproportionate energy in the storytelling that compresses the time to consensus.

The discovery bottleneck in medicine is gone — the delivery bottleneck is about to become the only thing that matters

AlphaFold can already design proteins that could theoretically treat almost any disease. AI is compressing what used to take decades of painstaking research. The old bottleneck — figuring out what protein to build — is dissolving fast. What isn't dissolving is the infrastructure problem: getting those proteins into the right cells, in the right organs, at population scale, in patients who don't live near MD Anderson. The gap between what we can design and what we can actually deliver is about to become the defining constraint in medicine — exactly as compute availability became the defining constraint in AI. Whoever builds organ-specific delivery infrastructure first won't just treat more diseases. They'll own the platform through which every subsequent breakthrough reaches patients.

---

Topics: genetic medicine, mRNA therapeutics, cancer immunotherapy, FDA reform, clinical trials, biotech investing, regulatory policy, platform therapeutics, abscopal effect, messaging strategy, startup communications, drug development, SpaceX analogy, China competition, RNA medicine